| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 来那度胺; Lenalidomide (CC-5013) | CFN60128 | 191732-72-6 | C13H13N3O3 = 259.26 | 5mg | QQ客服：215959384 |
| Tipifarnib (R115777); Tipifarnib (R115777) | CFN60129 | 192185-72-1 | C27H22Cl2N4O = 489.4 | 5mg | QQ客服：215959384 |
| Stattic; Stattic | CFN60130 | 19983-44-9 | C8H5NO4S = 211.19 | 5mg | QQ客服：1457312923 |
| 比拉瑞塞; Birabresib (OTX015) | CFN60131 | 202590-98-5 | C25H22ClN5O2S = 491.99 | 5mg | QQ客服：1413575084 |
| Z-DEVD-FMK; Z-DEVD-FMK | CFN60132 | 210344-95-9 | C30H41FN4O12 = 668.66 | 5mg | QQ客服：215959384 |
| PD184352 (CI-1040); PD184352 (CI-1040) | CFN60133 | 212631-79-3 | C17H14ClF2IN2O2 = 478.67 | 5mg | QQ客服：2056216494 |
| 氟达拉滨; Fludarabine | CFN60134 | 21679-14-1 | C10H12FN5O4 = 285.23 | 5mg | QQ客服：1413575084 |
| PD173074; PD173074 | CFN60135 | 219580-11-7 | C28H41N7O3 = 523.67 | 5mg | QQ客服：2159513211 |
| 甲磺酸伊马替尼; Imatinib Mesylate (STI571) | CFN60136 | 220127-57-1 | C29H31N7O.CH4SO3 = 589.71 | 5mg | QQ客服：1413575084 |
| 盐酸柔红霉素; Daunorubicin HCl | CFN60137 | 23541-50-6 | C27H29NO10.HCl = 563.98 | 5mg | QQ客服：1457312923 |
| 阿卡地新; Acadesine (AICAR) | CFN60138 | 2627-69-2 | C9H14N4O5 = 258.2 | 5mg | QQ客服：1457312923 |
| Belnacasan (VX-765); Belnacasan (VX-765) | CFN60139 | 273404-37-8 | C24H33ClN4O6 = 509.0 | 5mg | QQ客服：3257982914 |
| SB216763; SB216763 | CFN60140 | 280744-09-4 | C19H12N2O2Cl2 = 371.22 | 5mg | QQ客服：215959384 |
| 多马莫德; Doramapimod (BIRB 796) | CFN60141 | 285983-48-4 | C31H37N5O3 = 527.66 | 5mg | QQ客服：215959384 |
| 西地尼布; Cediranib (AZD2171) | CFN60142 | 288383-20-0 | C25H27FN4O3 = 450.51 | 5mg | QQ客服：1413575084 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)